Controversy in Cancer Screening Prostate Cancer

Prostate cancer is the second most common cancer in men worldwide. Although PSA remains the most used test for screening, the limited specificity and an elevated rate of over diagnosis are a problem. Recently a number of novel biomarkers aiming to increase ability to select patients for biopsy and identify men at risk seem to be promising.

The debate will add some new perspective on the topic giving the audience the understanding of whether to screen, how often and with what.

Access

Public

Year

2023